DelveInsight’s ‘Cushing’s Syndrome Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Cushing’s Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cushing’s Syndrome pipeline domain.
For Cushing’s Syndrome emerging drugs, the Cushing’s Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Cushing’s Syndrome Pipeline Report
- Over 6+ Cushing’s Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Cushing’s Syndrome market would significantly increase market revenue.
- Leading Cushing’s Syndrome companies developing novel drug candidates to improve the Cushing’s Syndrome treatment landscape include Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, and others.
- Promising Cushing’s Syndrome pipeline therapies in various stages of development include Relacorilant, CRN 04894, Seliciclib, SPI-62, AZD 4017, ST-002, and others.
- In November 2022, Xeris Biopharma Holdings, Inc. announced that the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating the longer-term effects of levoketoconazole on cortisol levels, biomarkers of Cushing’s syndrome
- In September 2022, Sparrow Pharmaceuticals announced that the first patient in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome, has been dosed.
- In August 2022, the long-term outcomes of the open-label extension period of the Phase III LINC 3 study of Isturisa® were published in The European Journal of Endocrinology by Recordati Rare Diseases.
Request a sample and discover the recent breakthroughs happening Cushing’s Syndrome pipeline landscape in @ Cushing’s Syndrome Pipeline Report
Cushing’s Syndrome Overview
Cushing syndrome is caused by prolonged exposure to high cortisol levels in the blood. Iatrogenic corticosteroid use is the most common cause of cushingoid features, but some herbal preparations can also raise circulating corticosteroid levels, leading to Cushing syndrome. Cushing syndrome and hypercortisolism are terms that can be used interchangeably. Cushing disease is caused by an excess of ACTH-dependent cortisol caused by a pituitary adenoma and accounts for 80% of endogenous Cushing syndrome. Cushing syndrome has two main causes: endogenous hypercortisolism and exogenous hypercortisolism.
Endogenous hypercortisolism can be demonstrated with late-night salivary cortisol or a 24-hour urine free cortisol in the evaluation of suspected Cushing’s syndrome. Exogenous steroid tapering is the most effective treatment for iatrogenic Cushing syndrome. Chronic steroid use can suppress adrenal function, and it can take several months for normal adrenal function to return.
Cushing’s Syndrome Pipeline Analysis: Drug Profile
Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator, which is the cortisol receptor that is activated when cortisol levels are high. Relacorilant does not bind to any other hormone receptors in the body. Corcept is researching relacorilant as a possible treatment for a number of serious conditions, including Cushing’s syndrome and advanced adrenal, ovarian, and pancreatic cancer. Corcept owns Relacorilant, which is protected by composition of matter and method of use patents. In the United States, Relacorilant has been designated as an orphan drug for the treatment of Cushing’s syndrome and pancreatic cancer. A Phase III study is currently underway to assess the efficacy and safety of Relacorilant in patients with endogenous Cushing syndrome.
SPI-62: Sparrow Pharmaceuticals
SPI-62 is an oral, small molecule, highly potent, and selective HSD-1 inhibitor. It is being developed to treat cortisol excess conditions such as endogenous Cushing’s syndrome (Cushing’s) and autonomous cortisol secretion (ACS). SPI-62 demonstrated potent targeting of HSD-1 in the brain and liver, as well as significant lowering of cortisol levels in the liver, in five clinical trials. These studies also revealed a favorable safety and tolerability profile and glucose, HbA1c, cholesterol, and triglyceride improvements. It is currently being tested for Cushing syndrome treatment in the Phase II stage of development.
Cushing’s Syndrome Pipeline Therapies and Key Companies
- Datopotamab deruxtecan: Daiichi Sankyo
- JDQ443: Novartis
- MRTX849: Mirati Therapeutics
- INBRX-106: Inhibrx
- GB 1211: Galecto Biotech
- BBP 398: BridgeBio Pharma
- TGRX 326: Shenzhen TargetRx
- SRF388: Surface Oncology
- ABBV 514: AbbVie
Learn more about the Cushing’s Syndrome emerging pipeline therapies @Cushing’s Syndrome Clinical Trials
Cushing’s Syndrome Pipeline Therapeutics Assessment
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Monoclonal Antibody
- Small molecule
- Gene therapy
Scope of the Cushing’s Syndrome Pipeline Report
- Coverage: Global
- Key Cushing’s Syndrome Companies: Corcept Therapeutics (NASDAQ: CORT), Crinetics Pharmaceuticals (NASDAQ: CRNX), Cyclacel Pharmaceuticals (NASDAQ: CYCC), Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, and others.
- Key Cushing’s Syndrome Pipeline Therapies: Relacorilant, CRN 04894, Seliciclib, SPI-62, AZD 4017, ST-002, and others.
Dive deep into rich insights for Cushing’s Syndrome emerging therapies and assessment, visit @ Cushing’s Syndrome Emerging Therapies
Table of Contents
|2.||Cushing’s Syndrome Executive Summary|
|3.||Cushing’s Syndrome Overview|
|4.||Cushing’s Syndrome Pipeline Therapeutics|
|5.||Cushing’s Syndrome Pipeline: Late Stage Products (Phase III)|
|6.||Cushing’s Syndrome Pipeline: Mid Stage Products (Phase II)|
|7.||Cushing’s Syndrome Pipeline: Early Stage Products (Phase I/II)|
|8.||Cushing’s Syndrome Pipeline: Preclinical Stage Products|
|9.||Cushing’s Syndrome Pipeline: Discovery Stage Products|
|10.||Cushing’s Syndrome Pipeline Therapeutic Assessment|
|11.||Cushing’s Syndrome Pipeline: Inactive Products|
|12.||Collaborations Assessment- Licensing / Partnering / Funding|
|14.||Market Drivers and Barriers|
For further information on the Cushing’s Syndrome current pipeline therapeutics, reach out @ Cushing’s Syndrome Therapeutics Assessment
Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gene therapy In Cushing’s Syndrome companies, including Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, among others.
Cushing’s Syndrome Epidemiology
Cushing’s Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Cushing’s Syndrome epidemiology trends.
Endogenous Cushing’s Syndrome Pipeline
Endogenous Cushing’s Syndrome Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Endogenous Cushing’s Syndrome companies, including Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, among others.
Endogenous Cushing’s Syndrome Market
Endogenous Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gene therapy In Endogenous Cushing’s Syndrome companies, including Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, among others.
Endogenous Cushing’s Syndrome Epidemiology
Endogenous Cushing’s Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Endogenous Cushing’s Syndrome epidemiology trends.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Services
- Healthcare Business Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Healthcare Market Research Reports | Healthcare Business Consulting